PunchAbducted Plateau varsity student freed, hospitalisedBollywood HungamaRamayana: Bombay High Court grants anti-piracy protection to Ranbir Kapoor starrer ahead of November 5 releaseInquirer16 areas to experience dangerous heat levels Tuesday — PagasaThe Jerusalem PostShin Bet expands election interference probe to suspected Palestinian Authority funding - reportZDF heuteAktuelle Pressemitteilungen des ZDFCNN TürkBaşkan Topak, Avrupa Konseyi'nde Türkiye ve Ergene'yi anlattıThe South AfricanAmericans vote in midterms set to upend Donald Trump presidencyEuronewsRhodes floods: Cars swept away after torrential rain in Greece01net1 400 km d’autonomie et propulsion : la future Renault Mégane prépare une vraie révolution contre TeslaCNN بالعربيةهجوم سيبراني غير مألوف.. قراصنة يعبثون بثلاجات المتاجر بأوروبا ويتلفون الطعامInteriaNauczyciele powinni sprawdzać plecaki uczniów? Polacy zabrali głosABC NewsMidterm elections live updates: Voters heading to polls today for midterms
The Daily Newsstand · Free, Always
Tuesday, November 3, 2026

America's pharmaceutical industry is facing a 'monkey problem' & reason is China

Translate

America's pharmaceutical industry is facing a 'monkey problem' and the reason is China, now a Palantir-backed tech startup plans to solve it

AI-generated image for representation purpose

America's pharmaceutical industry is facing a lab monkey crisis because of AI. A TechCrunch report says that the rising costs and restrictions on imports are adding pressure on laboratories.

China has played a major role in supplying laboratory monkeys to the US. China, as stated in the report, accounted for nearly 60% of America's laboratory monkey imports before it banned exports in 2020. Facing supply constraints, American laboratories subsequently turned to Cambodia. However, a 2022 investigation found that wild-caught monkeys were falsely represented as captive-bred animals. Now, a startup backed by Palantir cofounder Joe Lonsdale plans to establish a large-scale monkey breeding facility in the US to help address the problem.

Palantir co-founder's startup aims to tackle monkey problem of American pharmaceutical industry

As stated in the report, Safer Human Medicine, said to be backed by Joe Lonsdale aims to eventually breed 30,000 macaques over the next twenty years. The proposed facility is intended to reduce American laboratories' dependence on imported monkeys, which are widely used in pharmaceutical research and testing.The shortage has become more pressing as AI helps researchers discover potential drugs faster, increasing the number of experimental treatments that may need to be tested.

However, the supply problem existed even before the recent growth of AI-assisted drug discovery.

Why is America facing a monkey shortage

As mentioned above, China was one of the key suppliers of laboratory monkeys to the US. Since the export ban in 2020, the pharmaceutical industry has been hit with shortages. This in turn has also added to the cost.As stated in the report, macaques reportedly cost around $3,000 in 2019. But today their prices have since climbed to more than $20,000 with China reportedly charging approximately $26,000 per macaque.

Why are monkeys important for pharmaceutical research

According to estimates, US laboratories import around 20,000 monkeys every year. Macaques are commonly used in medical experiments because of their biological similarities to humans. Researchers use them to study the safety, toxicity and biological effects of potential treatments before they move into human clinical trials.AI is also changing the drug discovery process. Researchers can use AI tools to identify potential medicines and generate more drug candidates in less time. However, promising candidates may still require laboratory studies, including animal testing, before human trials can begin.

View the original on Times of India →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.